Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minoxidil and finasteride together can lead to significant hair regrowth, often noticed gradually over time. Consistent use without stress is key, and while minoxidil helps regrow hair, finasteride prevents further loss.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

The brain resists updating its perception of gradual appearance changes, like hair loss, due to its preference for stability and reliance on an internal model. This delay in perception can make changes feel sudden once the brain finally updates its model.

The user has been using 0.5 mg dutasteride and 2.5 mg oral minoxidil for a year, recently adding microneedling and topical minoxidil, with some improvement but the crown remains the weakest area. Consistency and realistic expectations are advised, as progress is slow and coverage is challenging with fine hair.

The user is frustrated with hair loss treatments like finasteride, minoxidil, dutasteride, and oral minoxidil, which have been ineffective and caused scalp itching. They are skeptical about these treatments' effectiveness and consider alternative options like ketoconazole shampoo and RU58841.

The user experienced significant hair improvement using oral finasteride and minoxidil but is now facing a secondary hair shedding phase after nine months, possibly linked to weight loss or seasonal changes. Despite concerns, others in the conversation suggest that such shedding is normal and temporary.

Dutasteride may affect semen parameters but not significantly enough to impact fertility unless baseline fertility is already low. Finasteride and minoxidil are used for hair regrowth, with no side effects reported by one user.

The user switched from finasteride and topical minoxidil to dutasteride and oral minoxidil due to side effects but is experiencing further hair recession. They plan to double the dosage, despite mixed feedback on the effectiveness and potential side effects of the treatments.

Dutasteride takes 1-3 months to affect scalp DHT levels, not just a week. The prostate absorbs Dutasteride faster than the scalp due to different vascular networks and enzyme densities.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

The user experienced significant hair thickening after one year of using chewable finasteride (1.2 mg) and minoxidil (2.5 mg) without major side effects, except occasional low libido. The user sourced the treatments from Hims and noticed results around 5-6 months, with shedding lasting about two months.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

Improved hair density and texture after using 1mg oral finasteride and 5mg oral minoxidil for a year. The user is satisfied with the results, noting no significant side effects except reduced seminal volume.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The user experienced significant regrowth in the crown and hairline using 1.25mg finasteride daily for 13 months but noticed thinner scalp density. Suggestions included adding topical minoxidil or 0.5mg dutasteride, as scalp regrowth may lag behind other areas.

The user stopped oral treatments due to side effects and switched to a regimen of topical minoxidil, tretinoin, azelaic acid, and dermaneedling, with recent addition of topical finasteride. They are questioning the long-term effectiveness of non-hormonal methods and considering hair transplantation.

The user experiences immediate hair shedding linked to stress, unlike typical telogen effluvium, and is seeking answers. A suggestion was made to use spironolactone and topical minoxidil to address potential DHT-related shedding.

RU58841 remains active for several hours after application, and it's suggested to wait a few hours before washing it off to maintain its effectiveness. There is a concern about potential transfer to others if they touch the hair shortly after application.

The user is concerned about safely using RU58841 around cats and wonders if applying it 2 hours before a shower is as effective as leaving it overnight. The discussion focuses on the absorption time and effectiveness of RU58841.

Low-Level Laser Therapy (LLLT) is seen as a safe and effective method for maintaining hair and promoting regrowth in androgenetic alopecia (AGA) and male pattern baldness (MPB), with devices like the HairMax LaserComb® and iRestore helmet being popular. Some users and professionals are skeptical about its long-term effectiveness and cost.

A potential baldness cure, possibly PP405, might be available before the release of GTA 6, which is delayed to 2026 or 2027. There is skepticism about the effectiveness and release timeline of PP405.

The conversation is about the effectiveness of RU58841 after stopping its use. The user is concerned about losing results if there's a 4-5 day gap before the next bottle arrives.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Chronostim is a hair treatment with separate day and night formulas containing ingredients like lauric acid, glycyrrhetinic acid, and piroctone olamine. Users discuss its effectiveness for hair loss.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.